Progerin mislocalizes myocardin-related transcription factor in Hutchinson-Guilford Progeria syndrome.

Ryan von Kleeck, Paola Castagnino, Richard K Assoian

Open access · diamondAbstract read

In one paragraph

Article in Vascular biology (Bristol, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 54% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS.Cells · 2023
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan von KleeckDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia Pennsylvania, USA.

Paola CastagninoDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia Pennsylvania, USA.

Richard K AssoianDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia Pennsylvania, USA.ORCID 0000-0001-7635-6204

Translational Therapeutics (United States) · US

Funding

Arterial stiffening and SMC mechanobiology in Hutchinson-Guilford Progeria SyndromeR01AG062140 · NIA · UNIVERSITY OF PENNSYLVANIA · PI ASSOIAN, RICHARD · 2019 to 2023

$2.0M

NIA NIH HHS R01 AG062140

6 · The paper itself

Abstract

Hutchinson-Guilford Progeria syndrome (HGPS) is a rare genetic disease of premature aging and early death due to cardiovascular disease. The arteries of HGPS children and mice are pathologically stiff, and HGPS mice also display reduced arterial contractility. We recently showed that reduced contractility is an early event in HGPS and linked to an aberrantly low expression of smooth muscle myosin heavy chain (smMHC). Here, we have explored the basis for reduced smMHC abundance and asked whether it is a direct effect of progerin expression or a longer-term adaptive response.

Indexed as

arterial contractilityCArG genesMyh11myosin heavy chainsmooth muscle

Identifiers

PMID35441125

DOI10.1530/VB-21-0018

PMCPMC9012937

OpenAlexW4212920536

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.